CJC Peptide (CJC-1295): How It Works, Benefits, and Risks

CJC peptide almost always refers to CJC-1295, a synthetic copy of part of growth-hormone-releasing hormone (GHRH). It nudges your pituitary gland to release more of your own growth hormone (GH) and IGF-1. It comes as a long-acting form (CJC-1295 with DAC, ~6–8 day half-life) and a short-acting form (CJC-1295 without DAC, also called Modified GRF (1-29)). It is not FDA-approved for any use, and legitimate access is only through a licensed clinician and a compounding pharmacy [1][2].

What is the CJC peptide?

CJC-1295 is a lab-made peptide modeled on the first 29 amino acids of GHRH, which is the natural signal your brain uses to ask the pituitary for growth hormone [1]. It was developed in the early 2000s by ConjuChem Biotechnologies as a longer-lasting way to raise GH without injecting GH itself [1]. Because it works upstream — through your own pituitary — it is part of the growth hormone secretagogue family, alongside sermorelin and tesamorelin.

CJC-1295 vs. Modified GRF (1-29)

Confusingly, the name "CJC-1295" is used for two related but different peptides. "CJC-1295 with DAC" includes a Drug Affinity Complex (DAC) that binds to albumin in the blood and stretches the half-life to roughly 6–8 days [1]. "CJC-1295 without DAC" — properly called Modified GRF (1-29) — lacks that tail and is cleared within about 30 minutes [1]. They are sometimes sold under the same nickname even though they behave very differently in the body.

How CJC-1295 relates to GHRH and sermorelin

All three molecules — natural GHRH, sermorelin, and CJC-1295 — bind to the same receptor on pituitary cells. Sermorelin is identical to GHRH (1-29) and is FDA-approved as a diagnostic agent [6]. CJC-1295 adds four amino-acid substitutions that resist breakdown, which is why it acts longer than sermorelin [1]. Tesamorelin, an FDA-approved GHRH analog, is approved specifically for HIV-associated lipodystrophy and serves as a useful comparator for what regulated GHRH-class therapy looks like [7].

How does CJC-1295 work in the body?

Stimulating natural growth hormone release

CJC-1295 binds to the GHRH receptor on the pituitary gland and tells it to release a pulse of growth hormone [1]. Because the signal flows through your own pituitary, GH still comes out in pulses that follow the body's normal feedback controls — different from injecting recombinant human growth hormone, which floods the system with a steady level [1].

Effect on IGF-1 levels

When GH rises, the liver makes more insulin-like growth factor 1 (IGF-1). In the published phase I trial of CJC-1295, single doses raised mean GH concentrations 2- to 10-fold for up to six days and IGF-1 levels 1.5- to 3-fold for 9–11 days [2]. That long IGF-1 tail is the main reason researchers were interested — and also the main reason long-term safety needs more study, because chronically elevated IGF-1 has been linked in observational data to cancer risk [8].

CJC-1295 with DAC vs. CJC-1295 without DAC: what's the difference?

The DAC "tail" is the single biggest factor in how the peptide behaves. Modified GRF (1-29) produces a short, sharp GH pulse that mimics natural rhythm. CJC-1295 with DAC produces a broad, sustained rise in GH and IGF-1 that lasts for days [1][2].

Why is CJC often combined with ipamorelin?

CJC-1295 and ipamorelin act on different receptors. CJC works through the GHRH receptor; ipamorelin is a ghrelin-receptor agonist (a "GHRP") that triggers GH release through a second pathway [9]. In research and compounding-pharmacy practice, the two are commonly combined because the signals are additive — a CJC pulse plus an ipamorelin pulse produces more GH release than either alone, while ipamorelin is relatively selective and does not strongly raise cortisol or prolactin [9]. You can read more in our companion guide to ipamorelin.

Important caveat: combination-specific clinical trials are limited. Most evidence is mechanistic or from small studies of each peptide individually. Side effects of the two can overlap (headache, flushing, water retention), so combination use belongs under clinician oversight.

What are the potential benefits people seek from CJC peptide therapy?

People generally come to CJC-1295 looking for the downstream effects of higher GH and IGF-1. It is important to separate what the published trials show from what is reported anecdotally.

Body composition and lean muscle

Higher GH and IGF-1 are associated with increased lean mass and reduced fat mass in studies of GH-deficient adults [10]. CJC-1295 itself has not been shown in large trials to produce these outcomes; the phase I data only measured hormone levels, not body composition [2].

Recovery and sleep

GH release is naturally tied to deep sleep, and patients often report improved sleep quality on GHRH-class peptides. Robust clinical-trial evidence for CJC-1295 specifically improving recovery or sleep is not available.

Healthy aging

GH and IGF-1 fall with age, which has driven interest in GHRH-class peptides for healthy aging. But raising IGF-1 long-term is a double-edged sword — large epidemiology studies link higher IGF-1 to greater risk of certain cancers [8]. The honest answer is that the longevity case for chronic CJC-1295 is unproven.

What does the research actually show?

Published human research on CJC-1295 is limited to a small number of phase I studies. The pivotal trial gave single doses to healthy adults and showed dose-dependent increases in GH and IGF-1 lasting for days [2]. A separate phase I study confirmed similar pharmacokinetics [11]. Phase II development was discontinued in 2007 after a participant in a CJC-1295 trial died; the cause was not conclusively linked to the drug, but the program did not move forward [1]. There are no large, long-term efficacy or safety trials of CJC-1295 in humans.

What are the risks and side effects of CJC-1295?

Common reported side effects

• Injection-site redness, itching, or pain
• Flushing of the face and neck
• Headache
• Tingling (paresthesia) in the hands or feet
• Water retention and mild swelling
• Joint stiffness or aches
• Drops in blood sugar or, with chronic use, insulin resistance — because GH affects glucose metabolism [10]

Why CJC-1295 clinical trials were halted

ConjuChem stopped clinical development of CJC-1295 in 2007 after the death of a trial participant. Public reporting did not establish that CJC-1295 caused the death, but the program was discontinued and the company shifted focus [1]. Since then, no major sponsor has resumed phase II/III trials, which is why long-term safety in humans remains unknown.

Who should not use it

CJC-1295 is not appropriate for people with active or prior cancer, people who are pregnant or breastfeeding, children and adolescents, people with uncontrolled diabetes, or people with active pituitary disease. Anyone considering it should have a full medical evaluation. Competitive athletes should also know that CJC-1295 is on the WADA Prohibited List under "peptide hormones, growth factors, related substances and mimetics" [3].

Is CJC-1295 FDA approved or legal?

No. CJC-1295 is not FDA-approved for any indication, and it is not sold as a finished drug product [1]. In the United States, it can legally be dispensed only as a compounded preparation, prepared by a licensed 503A compounding pharmacy for an individual patient based on a prescription from a licensed clinician [4]. Vials sold online as "research peptides" or "not for human use" are not legal for patient use, and quality cannot be verified — that's the safety risk worth taking seriously.

CJC-1295 is one of several peptides currently under FDA review, with the Pharmacy Compounding Advisory Committee (PCAC) scheduled to discuss the 503A Bulks List on July 23–24, 2026 [5]. The outcome is not predictable, and the current legal status is unchanged.

How is CJC-1295 administered and dosed?

CJC-1295 is given by subcutaneous injection (a small needle just under the skin, usually in the abdomen). In clinical and compounding-pharmacy practice, the long-acting form (with DAC) is typically used once or twice a week, while the short-acting form (without DAC / Modified GRF 1-29) is used more frequently, often daily, to match the body's natural GH pulses. Specific dosing depends on the patient and the prescriber — this guide does not provide dosing recommendations because they must come from a clinician who knows your medical history.

What peptides stack well with CJC-1295?

In clinical and research practice, CJC-1295 is most often paired with peptides that complement its mechanism. These are not Chia protocols — they are combinations that appear together in the literature and in compounding-pharmacy formularies.

• CJC-1295 + ipamorelin. Different receptors (GHRH vs. ghrelin), additive GH release, and ipamorelin's relative selectivity for GH over cortisol [9]. Side effects can overlap (headache, flushing); combination-specific trial data are limited.
• CJC-1295 + sermorelin (uncommon). Both act on the GHRH receptor, so combining them is generally redundant. Most clinicians choose one or the other based on duration.
• CJC-1295 + BPC-157 (for active recovery use cases). BPC-157 is studied for tissue repair, while CJC-1295 supports the GH/IGF-1 axis that underlies healing [12]. Both are investigational; safety profiles need to be tracked together by a clinician.

How to access CJC peptide therapy through a licensed provider

If you want to explore CJC-1295 responsibly, the steps look the same wherever you go: a real clinical evaluation, baseline labs (often IGF-1 and a metabolic panel), a discussion of goals and risks, and — if appropriate — a prescription sent to a licensed 503A compounding pharmacy. Telehealth providers that focus on longevity peptides, including Chia, offer one route to that evaluation. The right provider is the one who is willing to say no when the answer is no, who explains the off-label status clearly, and who follows up with repeat labs.

Avoid "research-only" vials sold online without a prescription. Independent testing has repeatedly found mislabeled potency, bacterial contamination, and unrelated compounds in unregulated peptide products.

Frequently asked questions

Keep reading

Longevity Peptides

Sermorelin: How This Growth Hormone Peptide Works

Longevity Peptides

Sermorelin: How This GHRH Peptide Works, Uses, and Safety

Longevity Peptides

Tesamorelin and Ipamorelin: How These Growth Hormone Peptides Work